UniProt ID | RAB8A_HUMAN | |
---|---|---|
UniProt AC | P61006 | |
Protein Name | Ras-related protein Rab-8A | |
Gene Name | RAB8A | |
Organism | Homo sapiens (Human). | |
Sequence Length | 207 | |
Subcellular Localization |
Cell membrane Lipid-anchor Cytoplasmic side . Golgi apparatus . Recycling endosome membrane . Cell projection, cilium . Cytoplasmic vesicle, phagosome . Cytoplasmic vesicle, phagosome membrane Lipid-anchor Cytoplasmic side . Cytoplasm, cytoskeleto |
|
Protein Description | The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different sets of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion. That Rab is involved in polarized vesicular trafficking and neurotransmitter release. Together with RAB11A, RAB3IP, the exocyst complex, PARD3, PRKCI, ANXA2, CDC42 and DNMBP promotes transcytosis of PODXL to the apical membrane initiation sites (AMIS), apical surface formation and lumenogenesis. [PubMed: 20890297 Together with MYO5B and RAB11A participates in epithelial cell polarization] | |
Protein Sequence | MAKTYDYLFKLLLIGDSGVGKTCVLFRFSEDAFNSTFISTIGIDFKIRTIELDGKRIKLQIWDTAGQERFRTITTAYYRGAMGIMLVYDITNEKSFDNIRNWIRNIEEHASADVEKMILGNKCDVNDKRQVSKERGEKLALDYGIKFMETSAKANINVENAFFTLARDIKAKMDKKLEGNSPQGSNQGVKITPDQQKRSSFFRCVLL | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
3 | Ubiquitination | -----MAKTYDYLFK -----CCCCHHHHHH | 46.44 | - | |
3 | Acetylation | -----MAKTYDYLFK -----CCCCHHHHHH | 46.44 | - | |
3 | Ubiquitination | -----MAKTYDYLFK -----CCCCHHHHHH | 46.44 | - | |
3 | Acetylation | -----MAKTYDYLFK -----CCCCHHHHHH | 46.44 | 25953088 | |
4 | Phosphorylation | ----MAKTYDYLFKL ----CCCCHHHHHHH | 16.46 | 28796482 | |
5 | Phosphorylation | ---MAKTYDYLFKLL ---CCCCHHHHHHHH | 11.24 | 25884760 | |
7 | Phosphorylation | -MAKTYDYLFKLLLI -CCCCHHHHHHHHHH | 12.01 | 28152594 | |
17 | Phosphorylation | KLLLIGDSGVGKTCV HHHHHCCCCCCCEEE | 30.11 | 23911959 | |
23 | S-palmitoylation | DSGVGKTCVLFRFSE CCCCCCEEEEEEECC | 2.59 | 29575903 | |
49 | Phosphorylation | GIDFKIRTIELDGKR CEEEEEEEEEECCEE | 23.44 | 22985185 | |
64 | Phosphorylation | IKLQIWDTAGQERFR EEEEEECCCCHHHHH | 20.07 | 28857561 | |
72 | Phosphorylation | AGQERFRTITTAYYR CCHHHHHHHHHHHHH | 21.69 | 26824392 | |
74 | Phosphorylation | QERFRTITTAYYRGA HHHHHHHHHHHHHCC | 12.54 | 29978859 | |
75 | Phosphorylation | ERFRTITTAYYRGAM HHHHHHHHHHHHCCC | 14.60 | 29978859 | |
77 | Phosphorylation | FRTITTAYYRGAMGI HHHHHHHHHHCCCEE | 7.51 | 28060719 | |
78 | Phosphorylation | RTITTAYYRGAMGIM HHHHHHHHHCCCEEE | 10.50 | - | |
111 | Phosphorylation | RNIEEHASADVEKMI HCHHHHCCCCHHHHH | 27.23 | 25159151 | |
116 | Ubiquitination | HASADVEKMILGNKC HCCCCHHHHHHCCCC | 30.96 | 21906983 | |
116 | Ubiquitination | HASADVEKMILGNKC HCCCCHHHHHHCCCC | 30.96 | - | |
122 | Ubiquitination | EKMILGNKCDVNDKR HHHHHCCCCCCCCCC | 29.98 | - | |
132 | Phosphorylation | VNDKRQVSKERGEKL CCCCCHHHHHHHHHH | 22.06 | - | |
138 | Ubiquitination | VSKERGEKLALDYGI HHHHHHHHHHHHHHH | 41.71 | - | |
138 | Ubiquitination | VSKERGEKLALDYGI HHHHHHHHHHHHHHH | 41.71 | 21906983 | |
162 (in isoform 2) | Phosphorylation | - | 7.88 | 30622161 | |
164 (in isoform 2) | Phosphorylation | - | 17.04 | 30622161 | |
164 | Phosphorylation | NVENAFFTLARDIKA CHHHHHHHHHHHHHH | 17.04 | 30266825 | |
176 | Ubiquitination | IKAKMDKKLEGNSPQ HHHHHHHHCCCCCCC | 47.72 | - | |
181 | Phosphorylation | DKKLEGNSPQGSNQG HHHCCCCCCCCCCCC | 29.47 | 29255136 | |
185 | Phosphorylation | EGNSPQGSNQGVKIT CCCCCCCCCCCCCCC | 22.26 | 29255136 | |
190 | Ubiquitination | QGSNQGVKITPDQQK CCCCCCCCCCCCHHH | 47.92 | 21906983 | |
192 | Phosphorylation | SNQGVKITPDQQKRS CCCCCCCCCCHHHCC | 18.33 | 25159151 | |
197 | Ubiquitination | KITPDQQKRSSFFRC CCCCCHHHCCCCEEE | 48.92 | - | |
199 | Phosphorylation | TPDQQKRSSFFRCVL CCCHHHCCCCEEEEE | 38.23 | 24702127 | |
200 | Phosphorylation | PDQQKRSSFFRCVLL CCHHHCCCCEEEEEC | 32.22 | 23312004 | |
204 | Geranylgeranylation | KRSSFFRCVLL---- HCCCCEEEEEC---- | 1.82 | 8375503 | |
204 | Geranylgeranylation | KRSSFFRCVLL---- HCCCCEEEEEC---- | 1.82 | 8375503 | |
204 | Methylation | KRSSFFRCVLL---- HCCCCEEEEEC---- | 1.82 | - |
Modified Location | Modified Residue | Modification | Function | Reference |
---|---|---|---|---|
72 | T | Phosphorylation |
| 26824392 |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of RAB8A_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-181 AND SER-185, ANDMASS SPECTROMETRY. | |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-181; SER-185 ANDTHR-192, AND MASS SPECTROMETRY. | |
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-181 AND SER-185, ANDMASS SPECTROMETRY. | |
"Phosphoproteome of resting human platelets."; Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,Schuetz C., Walter U., Gambaryan S., Sickmann A.; J. Proteome Res. 7:526-534(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-181 AND SER-185, ANDMASS SPECTROMETRY. | |
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-181 AND SER-185, ANDMASS SPECTROMETRY. | |
Prenylation | |
Reference | PubMed |
"Isoprenylation of Rab proteins possessing a C-terminal CaaX motif."; Joberty G., Tavitian A., Zahraoui A.; FEBS Lett. 330:323-328(1993). Cited for: ISOPRENYLATION AT CYS-204. |